Articles related to LEUKEMIA

In this Original Investigation from JAMA, the authors discuss the results of a randomized clinical trial that included 208 patients with high- and intermediate-risk first relapse of B-cell acute lymphoblastic leukemia (ALL). Did postreinduction treatment with blinatumomab compared with chemotherapy, followed by hematopoietic stem cell transplant, result in a statistically significant difference in disease-free survival?

For the estimated 21,000 patients who will receive a diagnosis of chronic lymphocytic leukemia (CLL), 20% of them will have early-stage disease. Unfortunately, that 20% will not be offered treatment, as the current management of these patients follows a “watch-and-wait” paradigm. However, with the advent of better prognostic tools to identify patients at high risk, in addition to the recent approval of several novel oral agents with impressive efficacy, re-examining this approach now seems prudent.

This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results in trials of acalabrutinib, venetoclax, obinutuzumab, rituximab, LOXO-305, idelalisib, bendamustine, umbralisib, ublituximab, chlorambucil, lisocabtagene maraleucel, and others. 

From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when treating patients with CLL.

In this Q&A, Dr. Gautam Borthakur from the University of Texas MD Anderson Cancer Center talks with Clinical Advances in Hematology & Oncology about the goals, treatment options (including tailored treatment), differences in de novo vs. therapy-related, and other suggestions in patients with core-binding factor acute myeloid leukemia (AML).

Are traditional cytotoxic chemotherapies becoming a thing of the past? This study in the Journal of Clinical Oncology shows a move toward targeted agents, as a combination of obinutuzumab, ibrutinib, and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).